Cargando…
Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters
Validation of the new hemifacial spasm (HFS) questionnaire “HFS score” that captures both clinical (HFS clinical) and health-related quality of life (HRQOL) parameters (HFS subjective) in one tool and comparison with a global HRQOL questionnaire. Cross sectional, prospective validation study includi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205881/ https://www.ncbi.nlm.nih.gov/pubmed/33963897 http://dx.doi.org/10.1007/s00702-021-02343-x |
_version_ | 1783708552156676096 |
---|---|
author | Wabbels, Bettina Yaqubi, Ali |
author_facet | Wabbels, Bettina Yaqubi, Ali |
author_sort | Wabbels, Bettina |
collection | PubMed |
description | Validation of the new hemifacial spasm (HFS) questionnaire “HFS score” that captures both clinical (HFS clinical) and health-related quality of life (HRQOL) parameters (HFS subjective) in one tool and comparison with a global HRQOL questionnaire. Cross sectional, prospective validation study including 143 subjects (62 HFS patients and 81 healthy volunteers) from the University Eye Hospital Bonn. Patients were interviewed with the new HFS score and the SF-12 questionnaire prior to and 3 weeks after Botulinum neurotoxin A (BoNT-A) injection. All HRQOL-related questions (HFS subjective) were answered on a visual analogue scale (VAS) ranging from 0 (no complaints) to 100% (maximum complaints) by the patients themselves. Reproducibility was tested in a study extension with 10 patients by repeat interviews (telephone/personal). The new HFS score questionnaire provided a reliable clinical assessment and demonstrated that BoNT-A therapy significantly reduced frequency and severity of eye and cheek spasms (p < 0.001; Wilcoxon test). Relevant aspects of HRQOL of HFS patients were assessed with high accuracy and sensitivity. Significant improvements were achieved after BoNT-A injection in five out of eight HRQOL parameters (p ≤ 0.02; Wilcoxon test). Cronbach’s alpha of 0.818 demonstrated good internal consistency. Telephone survey provided comparable results to personal interviews. This new sensitive and specific HFS score seems a reliable instrument to monitor BoNT therapy and customize it to the needs of the individual HFS patient—in clinical studies and daily clinical practice. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00702-021-02343-x. |
format | Online Article Text |
id | pubmed-8205881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-82058812021-07-01 Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters Wabbels, Bettina Yaqubi, Ali J Neural Transm (Vienna) Neurology and Preclinical Neurological Studies - Original Article Validation of the new hemifacial spasm (HFS) questionnaire “HFS score” that captures both clinical (HFS clinical) and health-related quality of life (HRQOL) parameters (HFS subjective) in one tool and comparison with a global HRQOL questionnaire. Cross sectional, prospective validation study including 143 subjects (62 HFS patients and 81 healthy volunteers) from the University Eye Hospital Bonn. Patients were interviewed with the new HFS score and the SF-12 questionnaire prior to and 3 weeks after Botulinum neurotoxin A (BoNT-A) injection. All HRQOL-related questions (HFS subjective) were answered on a visual analogue scale (VAS) ranging from 0 (no complaints) to 100% (maximum complaints) by the patients themselves. Reproducibility was tested in a study extension with 10 patients by repeat interviews (telephone/personal). The new HFS score questionnaire provided a reliable clinical assessment and demonstrated that BoNT-A therapy significantly reduced frequency and severity of eye and cheek spasms (p < 0.001; Wilcoxon test). Relevant aspects of HRQOL of HFS patients were assessed with high accuracy and sensitivity. Significant improvements were achieved after BoNT-A injection in five out of eight HRQOL parameters (p ≤ 0.02; Wilcoxon test). Cronbach’s alpha of 0.818 demonstrated good internal consistency. Telephone survey provided comparable results to personal interviews. This new sensitive and specific HFS score seems a reliable instrument to monitor BoNT therapy and customize it to the needs of the individual HFS patient—in clinical studies and daily clinical practice. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00702-021-02343-x. Springer Vienna 2021-05-08 2021 /pmc/articles/PMC8205881/ /pubmed/33963897 http://dx.doi.org/10.1007/s00702-021-02343-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Neurology and Preclinical Neurological Studies - Original Article Wabbels, Bettina Yaqubi, Ali Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters |
title | Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters |
title_full | Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters |
title_fullStr | Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters |
title_full_unstemmed | Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters |
title_short | Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters |
title_sort | validation of a new hemifacial spasm grading questionnaire (hfs score) assessing clinical and quality of life parameters |
topic | Neurology and Preclinical Neurological Studies - Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205881/ https://www.ncbi.nlm.nih.gov/pubmed/33963897 http://dx.doi.org/10.1007/s00702-021-02343-x |
work_keys_str_mv | AT wabbelsbettina validationofanewhemifacialspasmgradingquestionnairehfsscoreassessingclinicalandqualityoflifeparameters AT yaqubiali validationofanewhemifacialspasmgradingquestionnairehfsscoreassessingclinicalandqualityoflifeparameters |